Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$1.69 -9.1%	$2.06	$0.77 ▼ $4.08	$233.70M	1.4	887,159 shs	802,863 shs
IZTC Invizyne Technologies	$10.85 -0.4%	$12.72	$8.50 ▼ $23.00	$67.83M	N/A	37,647 shs	8,639 shs
PVLA Palvella Therapeutics	$22.93 -3.9%	$24.66	$6.20 ▼ $29.27	$253.22M	0.1	71,627 shs	66,061 shs
TSVT 2seventy bio	$4.99 -0.2%	$4.64	$2.29 ▼ $5.30	$265.61M	1.04	622,054 shs	1.14 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	-1.59%	-2.11%	+27.40%	-40.38%	+9.41%
IZTC Invizyne Technologies	0.00%	+1.49%	+9.45%	-37.77%	+1,088,999,900.00%
PVLA Palvella Therapeutics	-2.45%	-2.89%	-0.50%	+71.78%	+2,385,999,900.00%
TSVT 2seventy bio	0.00%	+0.20%	+1.01%	+83.82%	+5.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPX Compass Therapeutics	3.1816 of 5 stars	4.6	1.0	0.0	0.0	1.8	5.0	0.0
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	3.5558 of 5 stars	4.6	0.0	0.0	0.0	3.3	2.5	0.6
TSVT 2seventy bio	1.9283 of 5 stars	2.1	2.0	0.0	0.0	3.4	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	3.11	Buy	$13.38	691.42% Upside
IZTC Invizyne Technologies	0.00	N/A	N/A	N/A
PVLA Palvella Therapeutics	3.13	Buy	$44.43	93.76% Upside
TSVT 2seventy bio	2.29	Hold	$5.60	12.22% Upside

Current Analyst Ratings Breakdown

Latest IZTC, PVLA, CMPX, and TSVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/30/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/24/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
4/22/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/21/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/21/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/9/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
4/8/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
4/4/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $24.00
4/2/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/2/2025	CMPX Compass Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $6.00

(Data available from 5/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	274.94	N/A	N/A	$1.17 per share	1.44
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	$42.81M	5.91	N/A	N/A	$21.66 per share	1.06
TSVT 2seventy bio	$37.86M	7.02	N/A	N/A	$5.04 per share	0.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$42.49M	-$0.37	N/A	N/A	N/A	N/A	-32.37%	-30.67%	5/12/2025 (Estimated)
IZTC Invizyne Technologies	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	-$24.54M	-$12.10	N/A	N/A	N/A	N/A	-80.93%	-59.55%	5/13/2025 (Estimated)
TSVT 2seventy bio	-$217.57M	-$1.12	N/A	N/A	N/A	-207.25%	-53.65%	-23.67%	5/14/2025 (Estimated)

Latest IZTC, PVLA, CMPX, and TSVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	TSVT 2seventy bio	-$0.10	N/A	N/A	N/A	$13.96 million	N/A
5/12/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	N/A	N/A	N/A	N/A	N/A
3/25/2025	Q4 2024	TSVT 2seventy bio	-$0.23	-$0.31	-$0.08	-$0.37	$12.84 million	$2.93 million
2/27/2025	Q4 2024	CMPX Compass Therapeutics	-$0.10	-$0.11	-$0.01	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	31.84	31.84
IZTC Invizyne Technologies	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	4.82	4.82
TSVT 2seventy bio	N/A	4.95	4.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
IZTC Invizyne Technologies	N/A
PVLA Palvella Therapeutics	40.11%
TSVT 2seventy bio	93.90%

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	28.50%
IZTC Invizyne Technologies	N/A
PVLA Palvella Therapeutics	6.39%
TSVT 2seventy bio	7.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	20	138.28 million	98.38 million	Not Optionable
IZTC Invizyne Technologies	N/A	6.25 million	N/A	N/A
PVLA Palvella Therapeutics	N/A	11.04 million	10.50 million	N/A
TSVT 2seventy bio	440	53.23 million	47.87 million	Optionable

IZTC, PVLA, CMPX, and TSVT Headlines

Recent News About These Companies

2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Marshall Wace LLP

May 3 at 3:47 AM | marketbeat.com

2seventy bio, Inc. (NASDAQ:TSVT) Receives $5.60 Average Price Target from Analysts

May 2, 2025 | americanbankingnews.com

2seventy bio, Inc. (NASDAQ:TSVT) Given Average Recommendation of "Hold" by Brokerages

May 1, 2025 | marketbeat.com

2seventy bio (NASDAQ:TSVT) Earns Sell (E+) Rating from Weiss Ratings

April 27, 2025 | marketbeat.com

2seventy bio (NASDAQ:TSVT) Earns "Sell (E+)" Rating from Weiss Ratings

April 26, 2025 | americanbankingnews.com

2seventy bio, Inc. (NASDAQ:TSVT) Sees Significant Drop in Short Interest

April 21, 2025 | marketbeat.com

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

April 16, 2025 | businesswire.com

Weiss Ratings Reiterates Sell (D-) Rating for 2seventy bio (NASDAQ:TSVT)

April 10, 2025 | marketbeat.com

2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year

March 27, 2025 | markets.businessinsider.com

2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

March 25, 2025 | businesswire.com

Jessica Snow Sells 2,298 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock

March 20, 2025 | insidertrades.com

2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's Why

March 17, 2025 | zacks.com

2seventy Bio price target lowered to $5 from $6 at Morgan Stanley

March 14, 2025 | markets.businessinsider.com

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

March 14, 2025 | businesswire.com

2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells $25,350,607.23 in Stock

March 14, 2025 | insidertrades.com

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

March 13, 2025 | msn.com

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVT

March 12, 2025 | prnewswire.com

Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders

March 11, 2025 | businesswire.com

2seventy bio accepts Bristol Myers’ takeover bid

March 11, 2025 | thepharmaletter.com

Biotech Stock 2seventy bio, Inc. (Nasdaq: TSVT) Soars on Acquisition News

March 11, 2025 | investorideas.com

TSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to Shareholders

March 11, 2025 | tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IZTC, PVLA, CMPX, and TSVT Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$1.69 -0.17 (-9.14%)

Closing price 04:00 PM Eastern

Extended Trading

$1.70 +0.01 (+0.59%)

As of 07:49 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Invizyne Technologies NASDAQ:IZTC

$10.85 -0.04 (-0.37%)

As of 05/5/2025

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Palvella Therapeutics NASDAQ:PVLA

$22.93 -0.93 (-3.90%)

As of 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

2seventy bio NASDAQ:TSVT

$4.99 -0.01 (-0.20%)

Closing price 04:00 PM Eastern

Extended Trading

$5.00 +0.00 (+0.10%)

As of 06:20 PM Eastern

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time